- Impact Factor: 2.634
- Indexed In: PubMed: MEDLINE; Indexed in PubMed Central
- Publication is subject to payment of an article processing charge (APC)
- Submit here
Integrative Cancer Therapies (ICT) is a peer-reviewed open access journal which focuses on a comprehensive model of integrative cancer treatment with an emphasis on scientific understanding of alternative and traditional medicine therapies. Please see the Aims and Scope tab for further information.
This journal is a member of the Committee on Publication Ethics (COPE).
Submit your manuscript today at http://mc.manuscriptcentral.com/ict Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access article processing charge (APC) information
Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons license.
The APC for this journal is currently 2000 USD.
As of 1st January 2020, the APC will increase to 2200 USD. The APC charged is based on the date of original peer review submission. Articles submitted before 1st January 2020 will remain eligible for the lower APC, regardless of the article's date of acceptance.
The article processing charge (APC) is payable only if your article is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.
Please direct any queries to firstname.lastname@example.org.
This journal changed its publication mode from subscription to open access in 2016.
Integrative Cancer Therapies focuses on a new and growing movement in cancer treatment. The journal emphasizes scientific understanding of alternative and traditional medicine therapies, and the responsible integration of both with conventional health care. Integrative care includes therapeutic interventions in diet, lifestyle, exercise, stress care, and nutritional supplements, as well as experimental vaccines, chrono-chemotherapy, and other advanced treatments.
The journal presents scientifically rigorous original research, case studies, current literature reviews, educational roundtables, and commentary on key topics such as:
- Treatment strategies
- Evaluations of current therapies
- Models for integrating complementary and conventional treatment in clinical practice
- Interventions from alternative and traditional medicine
- Implementing quality-of-life assessment and counseling in the clinical setting
- Cancer rehabilitation during and following cancer treatments
- Potential interactions of cancer chemotherapy drugs with frequently used dietary supplements
- Implementing integrative cancer care strategies into oncology practice
- Relevant molecular mechanisms and biology behind integrative approaches
- Impact of timing of chemotherapy administration on toxicity
- Response, and outcome by leading oncologists
- Researchers, and health-care professionals
Three unique features of this publication are:
Integrative Grand Rounds: Insightful case studies from all viewpoints of case management plus commentary from the editors.
Point/Counterpoint: Lively discussions of controversial issues such as the interaction of antioxidants supplements and cancer chemotherapy or the effects of soy in treating breast cancer.
Patient's Perspective: Authoritative analysis of new treatments being actively used by patients.
This journal will be of particular interest to: medical, surgical, and radiation oncologists; clinical specialists frequently concerned with cancer such as urologists, gynecologists and women's health specialists; oncology and medical nurses; chiropractors; dietitians; pharmacists; and sophisticated lay people.
|Keith I. Block, MD||University of Illinois at Chicago, Institute for Integrative Cancer Care, USA|
|Penny Block, PhD||Block Center for Integrative Cancer Treatment, USA|
|Gail Mahady, PhD||University of Illinois, USA|
|Peying Yang, PhD||MD Anderson Cancer Center, University of Texas, USA|
|Charlotte Gyllenhaal, PhD||Institute for Integrative Cancer Care, USA|
|Jacob Shoham, MD, PhD||Bar-Ilan University, Ramat-Gan, Israel|
|Jim Grutsch, PhD||James F Grutsch & Associates, Wilmette, IL, USA|
|Donald Abrams, MD||University of California, San Francisco, USA|
|Lorenzo Cohen, PhD||M.D. Anderson Cancer Center, USA|
|William Hrushesky, MD||Rhythmalyltics, Inc, West Orange, NJ, USA|
|Wayne Jonas, MD||Uniformed Services University of the Health Sciences, USA|
|Susan Lutgendorf, PhD||University of Iowa, Iowa City, Iowa, USA|
|Robert A. Nagourney, MD||Rational Therapeutics Inc, USA|
|Robert Newman, PhD||Phoenix Biotechnology, San Antonio TX, USA|
|Julia Rowland, PhD||Smith Center for Healing and the Arts, USA|
|Andrew Weill, MD||University of Arizona, Tucson, AZ, USA|
|Christa Walker||SAGE Publishing, USA|
|Lise Alschuler, ND, FABNO||TAP Integrative, Green Bay, WI, USA|
|Lynda G. Balneaves, PhD||University of Manitoba, Winnipeg, Manitoba, Canada|
|Claudio Battaglini, PhD||University of North Carolina, Chapel Hill, NC, USA|
|Eran Ben-Arye, MD||Lin Medical Center, and Technicon-Israel Institute of Technology, Haifa, Israel|
|Anupam Bishayee, Pharm D, PhD||Larkin Health Sciences Institute, Miami, FL, USA|
|Massimo Bonucci, MD||San Feliciano Hospital, Rome, Italy|
|Amit Budhraja, PhD||St Jude's Children's Research Hospital, Memphis, USA|
|Terence Bugno, MD||Northern Illinois Center for Cancer Care, USA|
|Linda Carlson, PhD||University of Calgary, Alberta, Canada|
|Alejandro Chaoul, PhD||M.D. Anderson Cancer Center, Houston, TX, USA|
|Qi Chen, PhD||University of Kansas Medical Center, Kansas City, KS, USA|
|Nicole Culos-Reed, PhD||University of Calgary, Alberta, Canada|
|Yibin Feng, PhD||University of Hong Kong, Pokfulam, Hong Kong|
|Michael Foley, PhD||Idaho State University, Pocatello, Idaho, USA|
|Moshe Frenkel, MD||Meir Medical Center, Israel|
|Catherine Granger, PhD||Royal Melbourne Hospital, Australia|
|Reid Hayward||University of Northern Colorado, USA|
|Judith Jacobson, MD||Columbia University College of Physicians and Surgeons, USA|
|Miek Jong||Mid Sweden University, Sundsvall, Sweden|
|Omer Kucuk, MD||Emory University, Atlanta, GA, USA|
|Judith Lacey, MBBS, FRACGP, FAChPM (RACP)||Chris O’Brien Lifehouse Comprehensive Cancer Centre, Camperdown NSW, Australia|
|Elena Ladas, PhD||Columbia University, New York, NY, USA|
|Alexander Lucas, PhD||Virginia Commonwealth University School of Medicine, Richmond VA USA|
|Jun J. Mao, MD, MSCE||Memorial Sloan-Kettering Cancer Center, New York, NY, USA|
|Michael McCulloch, PhD||Pine Street Foundation, San Francisco, CA, USA|
|Dwight McKee, MD||Mederi Foundation, Ashland, OR and Life Plus International, Batesville, AR, USA|
|Mark Myers||Block Center for Integrative Cancer Treatment, USA|
|Byeongsang Oh, PhD||University of Sydney, Sydney, Australia|
|Patrizia Pasanisi||Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy|
|Greg Plotnikoff, MD||Minnesota Personalized Medicine, Minneapolis, MN, USA|
|Pratheeshkumar Poyil, PhD||King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|
|Mark Renneker, MD||University of California, San Francisco, USA|
|Waheed Roomi, PhD||Dr Rath Research Institute, Santa Clara, CA, USA|
|Friedeman Schad, MD||Hospital Havelhoehe, Berlin, German|
|Dugald Seeley, ND, MSc||Ottawa Integrative Cancer Centre, Ottawa, Ontario, Canada|
|Victor S. Sierpina, MD||University of Texas, Medical Branch at Galveston, USA|
|Judith Smith, PharmD||University of Texas Health Science Center at Houston, USA|
|Leanna Standish, ND||Bastyr University, Kenmore, WA, USA|
|Stephen Sze, PhD||University of Hong Kong, Pokfulam, Hong Kong|
|Walter Tsang, MD||Lifestyle Medical, Redlands CA|
|Chin-Kun Wang, PhD||Chung Shan Medical University, Taichung|
|Wong-Bo Wang, PhD||National Taiwan University, Taipei|
|Raimond Wong, MD||Juravinski Cancer Center, Hamilton, Ontario, Canada|
|Shun-Fa Yang||Chung Shan Medical University, Taichung, Taiwan|
|Hung-Rong Yen, MD, PhD||China Medical University Hospital, Taiwan|
|Hwa Seung Yoo, PhD||Daejon University, Daejon, South Korea|
|Seong Woo Yoon, MD, PhD||Kyung-Hee University, Gangdong, South Korea|
|Yingchun Zeng||The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/ict to to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Please also be sure to look over the submission checklist here before submitting.
Only manuscripts of sufficient quality that meet the aims and scope of Integrative Cancer Therapies will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Please Read the Manuscript Submission Guidelines below before submitting your manuscript here:
- Open Access
- Article processing charge (APC)
- What do we publish?
3.1 Aims & scope
3.2 Article types
3.3 Writing your paper
3.3.1 Making your article discoverable
- Editorial policies
4.1 Peer Review Policy
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines
- Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement
- Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplemental material
6.4 Reference style
6.5 English language editing services
- Submitting your manuscript
7.1 How to submit your manuscript
7.2 Title, keywords and abstracts
7.3 Information required for completing your submission
- On acceptance and publication
8.1 SAGE Production
8.2 Continuous publication
8.3 Promoting your article
- Further information
Integrative Cancer Therapies is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons licence.
The APC for this journal is currently $2,000 USD.
The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.
Before submitting your manuscript to Integrative Cancer Therapies, please ensure you have read the Aims & Scope.
Types of manuscripts accepted:
- Research articles should contain the following sections: Introduction (with brief literature review), Methods, Results, Discussion, and Conclusions, and may be up to 35 double-spaced manuscript pages in length. Studies submitted should conscientiously adhere to ethical principles and practices, including informed consent in experiments involving human subjects, and humane practices in experiments on laboratory animals, and must mention obtaining ethical approval from the appropriate institutional board.
- Brief reports on preliminary research projects, of up to 10 manuscript pages, are also welcomed.
- Review papers should include scholarly considerations and clinical implications, and may be up to 65 double-spaced manuscript pages in length.
- Case reports should explain the significance of the case, including relevant patient information, results of diagnostic tests, description of treatment and outcome, and may be up to 10 double-spaced manuscript pages in length.
- Educational articles provide shorter summaries of the state of research or practice in a facet of integrative cancer treatment. They may be up to 45 double-spaced manuscript pages in length, should include a reference list, and should chiefly address the interests of practitioners.
- Letters to the Editor: A letter to the Editor is a brief communication that either addresses the contents of a published article, or is a correspondence unrelated to a specific article. Its purpose is to make corrections, provide alternative viewpoints, or offer counter arguments. Avoid logical fallacies and ad hominem attacks. Letters to the Editor must be written in a professional tone and include references to support all claims if appropriate.
A letter to the Editor unrelated to a specific article should not exceed 500 words or have more than 3 references. A letter to the Editor pertaining to a recently published article or to be published concurrently with an article within the journal should not exceed 800 words or have more than 5 references. If an abstract is included, it will automatically be made the first paragraph. Letters should not include figures or research material. Letters to the editor are not charged an APC.
- Commentaries are by invitation only. These are short summaries of significant recent and forthcoming papers, published elsewhere, that provide additional insights, new interpretations or speculation on the relevant topic. These manuscripts may include models, which due to space limitations were not included or discussed in the original paper. Commentaries may be written in free form, meaning that they do not need to be structured as a research paper, however it must include an abstract of 150-200 words. They should be between 1000-2000 words and have no more than 25 references. Please include keywords for indexing purposes. Figures are encouraged, but no more than three. Please give your commentary a brief title and add the phrase “Comment on (citation to your original article).” underneath the keywords. Commentary material may be peer reviewed at the editor’s discretion.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.
Following a preliminary triage to eliminate submissions unsuitable for Integrative Cancer Therapies all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication. If your paper should be considered for fast-track publication, please explain why.
The journal’s policy is to have manuscripts reviewed by two expert reviewers. Integrative Cancer Therapies utilizes a single-blind peer review process in which the reviewer’s name and information is withheld from the author. Reviewers may at their own discretion opt to reveal their names to the author in their review but our standard policy practice is for their identities to remain concealed. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor-in-Chief who then makes the final decision.
As part of the submission process you will be asked to provide the names of up to three peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).
Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor / Board member will have no involvement in the decision-making process.
Integrative Cancer Therapies is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for Integrative Cancer Therapies can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors. The list of authors should include all those who can legitimately claim authorship. This is all those who:
(i) Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
(ii) Drafted the article or revised it critically for important intellectual content,
(iii) Approved the version to be published,
(iv) Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Integrative Cancer Therapies requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Integrative Cancer Therapies to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
Medical research involving human subjects must be conducted according to the World Medical Association declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles and case studies, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file. For more information on this, please see COPE's best practices.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.
Integrative Cancer Therapies endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and metaanalyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
At SAGE we are committed to facilitating openness, transparency and reproducibility of research. Integrative Cancer Therapies requests all authors to share their research data in a suitable public repository as a condition of publication. This is subject to ethical considerations and in such cases the journal editor may grant an exception and authors should contact the Editorial Office at email@example.com. Authors are also required to include a data accessibility statement in their manuscript file and to follow data citation principles. For more information please visit the SAGE Author Gateway, which includes information about SAGE’s partnership with the data repository Figshare.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
Integrative Cancer Therapies and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Integrative Cancer Therapies publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred formats for your manuscript are Word, RTF, XLS. LaTeX files are NOT accepted. The text should be double-spaced throughout and with a minimum of 3cm for left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
Figures supplied in color will appear in color online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For more information please refer to our guidelines on submitting supplemental files, which can be found within our Manuscript Submission Guidelines page.
Integrative Cancer Therapies adheres to the AMA reference style. Please review the guidelines on AMA to ensure your manuscript conforms to this reference style.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Integrative Cancer Therapies is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/ict to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. The affiliation listed on the manuscript should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all. Articles are batched every quarter, and are then available in the Archive.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximize your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Integrative Cancer Therapies editorial office as follows:
Charlotte Gyllenhaal, Ph.D.,
Managing Editor, Integrative Cancer Therapies
Block Center for Integrative Cancer Treatment
5230 Old Orchard Road
Skokie IL 60077